Carlos Delgado

Effect of the November 2023 Medicare Benefits Schedule PSA Testing Reform on National Utilisation, Diagnostic Activity, and Health-System Expenditure in Australia

Background/Objectives: On 1 November 2023, the Medicare Benefits Schedule (MBS) introduced major reforms to prostate-specific antigen (PSA) testing in Australia, extending the minimum re-test interval for average-risk men (item 66655) from 12 to 23 months and introducing a new an...